Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Ismaningerstr. 22, 81675 Munich, Germany.
Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S126-38. doi: 10.1007/s00259-011-2028-1.
Imaging of angiogenesis has become increasingly important with the rising use of targeted antiangiogenic therapies like bevacizumab (Avastin). Non-invasive assessment of angiogenic activity is in this respect interesting, e.g. for response assessment of such targeted antiangiogenic therapies. One promising approach of angiogenesis imaging is imaging of specific molecular markers of the angiogenic cascade like the integrin α(v)β(3). For molecular imaging of integrin expression, the use of radiolabelled peptides is still the only approach that has been successfully translated into the clinic. In this review we will summarize the current data on imaging of α(v)β(3) expression using radiolabelled RGD peptides with a focus on tracers already in clinical use. A perspective will be presented on the future clinical use of radiolabelled RGD peptides including an outlook on potential applications for radionuclide therapy.
随着贝伐单抗（阿瓦斯汀）等靶向抗血管生成疗法的应用日益增多，血管生成的影像学检查变得越来越重要。在这方面，对血管生成活性的非侵入性评估很有趣，例如，可用于评估此类靶向抗血管生成疗法的疗效。血管生成成像的一个很有前途的方法是对血管生成级联的特定分子标志物进行成像，如整合素α(v)β(3)。为了对整合素表达进行分子成像，使用放射性标记的肽仍然是唯一已成功转化为临床应用的方法。在这篇综述中，我们将总结使用放射性标记的 RGD 肽对α(v)β(3)表达进行成像的最新数据，重点介绍已在临床应用中的示踪剂。本文还将展望放射性标记 RGD 肽在未来的临床应用，包括对放射性核素治疗的潜在应用的展望。
